Clostridium novyi-NT in cancer therapy

Research output: Contribution to journalReview articlepeer-review


The attenuated anaerobic bacterium Clostridium novyi-NT (C. novyi-NT) is known for its ability to precisely germinate in and eradicate treatment-resistant hypoxic tumors in various experimental animal models and spontaneously occurring canine sarcomas. In this article, we review the therapeutic and toxicologic aspects of C. novyi-NT therapy, key challenges and limitations, and promising strategies to optimize its performance via recombinant DNA technology and immunotherapeutic approaches, to establish C. novyi-NT as an essential tool in cancer therapy.

Original languageEnglish (US)
Pages (from-to)144-152
Number of pages9
JournalGenes and Diseases
Issue number2
StatePublished - Jun 1 2016


  • Bacteria
  • Bacterial cancer therapy
  • Cancer
  • Clostridium
  • Clostridium novyi-NT
  • Hypoxia
  • Immunotherapy

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Genetics(clinical)
  • Cell Biology


Dive into the research topics of 'Clostridium novyi-NT in cancer therapy'. Together they form a unique fingerprint.

Cite this